DXS International (AQSE:DXSP) Change In Receivables: £0.51 Mil (TTM As of Apr. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is DXS International Change In Receivables?

DXS International AQSE:DXSP Change In Receivables is £0.51 Mil as of Apr. 2025. The stock has 5 warning signs investors should review.

DXS International's change in receivables for the quarter that ended in Apr. 2025 was £0.51 Mil. It means DXS International's Accounts Receivable declined by £0.51 Mil from Apr. 2024 to Apr. 2025 .

DXS International's change in receivables for the fiscal year that ended in Apr. 2025 was £0.51 Mil. It means DXS International's Accounts Receivable declined by £0.51 Mil from Apr. 2024 to Apr. 2025 .

DXS International's Accounts Receivable for the quarter that ended in Apr. 2025 was £0.32 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. DXS International's Days Sales Outstanding for the six months ended in Apr. 2025 was 16.88.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. DXS International's liquidation value for the six months ended in Apr. 2025 was £-1.34 Mil.

DXS International  (AQSE:DXSP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

DXS International's Days Sales Outstanding for the quarter that ended in Apr. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.321/3.47*91
=16.88

2. In Ben Graham's calculation of liquidation value, DXS International's accounts receivable are only considered to be worth 75% of book value:

DXS International's liquidation value for the quarter that ended in Apr. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.429-2.009+0.75 * 0.321+0.5 * 0
=-1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International Change In Receivables Related Terms

DXS International Change In Receivables Historical Data

* Premium members only.

The historical data trend for DXS International's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International Change In Receivables Chart

DXS International Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 0.23 -0.10 -0.44 0.51

DXS International Semi-Annual Data
Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.03 0.23 -0.10 -0.44 0.51

DXS International Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Apr. 2025 was £0.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of £0.51 Mil mean?
DXS International (AQSE:DXSP) has a Change In Receivables of £0.51 Mil as of Apr. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for DXS International and its competitors.
Is DXS International's Change In Receivables too high?
DXS International's current Change In Receivables is £0.51 Mil.
How does DXS International's Change In Receivables compare to VEEV and BTSG?
DXS International's Change In Receivables of £0.51 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Healthcare Providers & Services company?
A good Change In Receivables depends on the Healthcare Providers & Services industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for DXS International and its competitors. DXS International's current Change In Receivables is £0.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Fairly Valued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading 5% above its estimated fair value. The current Change In Receivables is £0.51 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current Change In Receivables is £0.51 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DXS International Business Description

Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.